Navigation Links
China Biologic Reports Financial Results for the Second Quarter and First Half of 2013
Date:8/6/2013

stable as the overall market continues to show steady signs of growth, however we will continue to closely monitor market trends related to albumin import volume, and will adjust our pricing and product shipments accordingly. In the coming quarters, we aim to preserve our margins through transitioning to a more profitable product mix and implementing efficient cost control measures. We were glad to achieve improved plasma utilization efficiency following the launch of Factor VIII products. For the second quarter, sales of Factor VIII contributed approximately 2% of total sales and we expect its sales contribution to gradually increase in the long run."

"During the second quarter, our new plasma station in Cao County, Shandong Province commenced plasma collection operations. Additionally, our Shandong Taibang production facility obtained renewed GMP certification from the China Food and Drug Administration ("CFDA") at the end of June, ahead of schedule. Additionally, in Guizhou, we halted production at this facility on June 1st as planned and remain on track with the facility upgrade plan. We currently expect to resume production at Guizhou Taibang in the first quarter of 2014."

Mr. Gao concluded, "The Company announced that it is has entered into a redemption agreement with Ms. Lin Ling Li, an individual shareholder of the Company and her spouse, pursuant to which the Company agreed to redeem 1,479,704 shares of its common stock, representing approximately 5.49% of the total common stock outstanding on August 2, 2013.  The redemption price is $20.00 per share, and the redemption shares will become treasure stock of the Company upon closing of the redemption.  We believe this share redemption will improve China Biologic's shareholder structure, enhance shareholder value and benefit other existing shareholders of the company. "

Second Quarter 2013 Financial PerformanceTotal sales in the second quarter of 2013 were $53.6
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BD and the College of American Pathologists Announce Strategic Alliance to Support Laboratory Quality and Performance in India and China
2. China Biologic Products to Report Second Quarter 2013 Financial Results
3. MEDTEC China 2013: Floor space sold out!
4. China Heart Valve Market and Heart Lung Machine Industry Global Analysis in New Research Reports
5. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
6. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
7. China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration
8. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
9. Research Report on Chinas High-End Medical Treatment Industry, 2013-2017
10. China Biologic Waived Application of Preferred Shares Rights Agreement
11. China Botanic Pharmaceutical Inc. Announces Withdrawal Of Request For Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:8/31/2015)... ... , ... Cosmetic Town Journal is an online plastic surgery ... successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients and connecting ... help. , It is clear that the Cosmetic Town aesthetic surgery community has ...
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – a member of ... fellow South Walton property management company, 360 Blue, in support of the ... of the world. The two companies will collect any unopened food items left in ...
(Date:8/31/2015)... ... 2015 , ... India Network Foundation, a non-profit US-based sponsor ... summarizes all available plans, plan maximums, pre-existing condition coverage limits and deductible in ... Network members make an informed decision regarding the care they want for their ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... management program that is unique to the Lake Orion area. This program is ... County. , WEmovestrong’s weight management program will incorporate group fitness and nutritional ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic leadership ... an industry leader in consumer-focused programs that have contributed to the company’s rapid ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... Research finds that for most adults in the Framingham ... mass index (BMI). However, for 13 percent// of the ... apolipoprotein A5 gene (APOA5), higher dietary fat was not ... and colleagues analyzed several common gene variants known as ...
... be a mantra to stay fit. New research suggests ... lifespan. ,Researchers at the University of Copenhagen ... of commonly used vitamin supplements, including vitamins A, E ... found that vitamin supplements appeared to raise, not lower, ...
... Olympics next year, Beijing has reserved many hospital beds for emergency ... outbreak. ,Beijing has planned to keep at least 6,350 ... infectious diseases like bird flu and SARS. ,China has ... bird flu. As a preventive measure, China took the intelligent step ...
... new analysis of both estrogen and estrogen plus progestin shows ... events in women starting// hormone therapy less than 10 years ... Yale and eight other study centers participating in the Kronos ... reduction in overall deaths among women aged 50 to 59 ...
... Davidson, 45, was basking in the happiness of her 27th ... she began to suffer// hot flashes, she dismissed them as ... but didn’t think so even in her wildest dreams. The ... symptoms of advancing menopause. At one instance, when she was ...
... study provides evidence that racial differences in the clinical ... to biological factors rather than differences in access to ... in a managed health care system found that in ... at significantly higher risk for being diagnosed with more ...
Cached Medicine News:Health News:Study Finds Dietary Fat Interacts With Genes 2Health News:Study Finds Dietary Fat Interacts With Genes 3Health News:Early Estrogen Therapy May Reduce Cardiovascular Risks 2Health News:More Aggressive Breast Cancer in Hispanics Independent of Health Care Utilization 2
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: